@entity1 with @entity262 ( @entity262 ) can suffer from disabling symptoms related to mast cell mediator release or mast cell infiltration, requiring mast cell eradication. In the present absence of any curative therapy, a recent case report describing the efficacy of @entity8778 showed promising results. In a pilot study, the efficacy of @entity8778 (0.10-0.13 mg/kg in a 2-hour infusion, days 1-5; repeated at 4-8 weeks until 6 cycles) was studied. Ten @entity1 with @entity262 with severe symptoms were treated. Four @entity1 were classified as having indolent or smoldering @entity5310 , 3 as having aggressive @entity262 , and 3 as having @entity262 with an accompanying @entity1583 . Nine @entity1 received 6 courses, 1 @entity1 stopped because of toxicodermia. All responded concerning signs, symptoms, and mast cell parameters (serum tryptase and urinary @entity112 metabolite excretion), although none achieved a complete remission. Prolonged follow-up is required, as response is ongoing in most cases. One @entity1 relapsed within 11 months and showed a second response. Side effects were mainly related to @entity236 . Single-agent @entity8778 is an effective and relatively safe treatment for severe @entity262 . The optimal dose and schedule need to be explored.

XXXX therapy for @entity262 .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity8778 :: ('MESH:D017338', 'Chemical') :: ['cladribine'] @entity5310 :: ('MESH:D008415', 'Disease') :: ['mastocytosis'] @entity262 :: ('MESH:D034721', 'Disease') :: ['SM', 'systemic mastocytosis'] @entity1583 :: ('MESH:D019337', 'Disease') :: ['hematologic malignancy'] @entity112 :: ('MESH:D006632', 'Chemical') :: ['histamine'] @entity236 :: ('MESH:D001855', 'Disease') :: ['bone marrow suppression']
@entity8778 :: (MESH:D017338,Chemical) :: ['Cladribine']
